Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1935 1
1962 1
1963 1
1964 1
1965 1
1966 1
1967 2
1968 4
1970 1
1971 4
1972 1
1973 1
1976 4
1977 1
1978 3
1979 1
1980 1
1981 2
1982 3
1983 1
1984 2
1985 3
1986 7
1987 1
1988 7
1989 6
1990 10
1991 10
1992 7
1993 8
1994 7
1995 11
1996 8
1997 11
1998 12
1999 18
2000 25
2001 24
2002 22
2003 39
2004 29
2005 59
2006 79
2007 124
2008 125
2009 130
2010 149
2011 194
2012 279
2013 272
2014 491
2015 499
2016 597
2017 653
2018 676
2019 751
2020 967
2021 1197
2022 1324
2023 1189
2024 1157
2025 1312
2026 598

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,546 results

Results by year

Filters applied: . Clear all
Page 1
Razi's Al-Hawi and saffron (Crocus sativus): a review.
Mollazadeh H, Emami SA, Hosseinzadeh H. Mollazadeh H, et al. Iran J Basic Med Sci. 2015 Dec;18(12):1153-66. Iran J Basic Med Sci. 2015. PMID: 26877844 Free PMC article. Review.
In the present study, we compare the data on saffron in Razi's Al-Hawi book with modern scientific studies. A computerized search of published articles was performed using MEDLINE, Scopus as well as native references. The search terms used were saffron, Crocus sativus, cro …
In the present study, we compare the data on saffron in Razi's Al-Hawi book with modern scientific studies. A computerized search of …
Reply.
Ghavidel-Parsa B, Bidari A. Ghavidel-Parsa B, et al. ACR Open Rheumatol. 2022 Jul;4(7):564-565. doi: 10.1002/acr2.11476. Epub 2022 Jun 21. ACR Open Rheumatol. 2022. PMID: 35726897 Free PMC article. No abstract available.
Characterization of Razi Bovine Kidney (RBK) Cell Line as a Sensitive Cell to Bovine Herpesvirus-1 (BoHV-1).
Masoumeh M, Mohsen L, Fattah SN, Ashraf M. Masoumeh M, et al. Arch Razi Inst. 2023 Oct 31;78(5):1528-1541. doi: 10.22092/ARI.2023.78.5.1410. eCollection 2023 Oct. Arch Razi Inst. 2023. PMID: 38590682 Free PMC article.
Viruses are obligate parasites that completely rely on host cells for survival and replication. Razi Bovine Kidney (RBK) cell line was introduced and developed by the Razi Vaccine and Serum Research Institute. ...
Viruses are obligate parasites that completely rely on host cells for survival and replication. Razi Bovine Kidney (RBK) cell line wa …
Immunogenicity and safety of RAZI recombinant spike protein vaccine (RCP) as a booster dose after priming with BBIBP-CorV: a parallel two groups, randomized, double blind trial.
Erfanpoor S, Banihashemi SR, Mokhbaeralsafa L, Kalantari S, Es-Haghi A, Nofeli M, Rezaei Mokarram A, Sadeghi F, Hajimoradi M, Razaz SH, Taghdiri M, Lotfi M, Khorasani A, Ansarifar A, Masoumi S, Mohazzab A, Filsoof S, Mohseni V, Shahsavan M, Gharavi N, Setarehdan SA, Rabiee MH, Fallah Mehrabadi MH, Solaymani-Dodaran M. Erfanpoor S, et al. BMC Med. 2024 Feb 20;22(1):78. doi: 10.1186/s12916-024-03295-1. BMC Med. 2024. PMID: 38378570 Free PMC article. Clinical Trial.
This study investigated the safety and immunogenicity of the Razi Cov Pars vaccine (RCP) as a heterologous booster dose in people primed with Beijing Bio-Institute of Biological Products Coronavirus Vaccine (BBIBP-CorV). ...
This study investigated the safety and immunogenicity of the Razi Cov Pars vaccine (RCP) as a heterologous booster dose in people pri …
Safety and Immunogenicity of Intranasal Razi Cov Pars as a COVID-19 Booster Vaccine in Adults: Promising Results from a Groundbreaking Clinical Trial.
Fallah Mehrabadi MH, Hajimoradi M, Es-Haghi A, Kalantari S, Noofeli M, Mokarram AR, Razzaz SH, Taghdiri M, Mokhberalsafa L, Sadeghi F, Mohseni V, Masoumi S, Golmoradi-Zadeh R, Rabiee MH, Solaymani-Dodaran M, Banihashemi SR. Fallah Mehrabadi MH, et al. Vaccines (Basel). 2024 Nov 5;12(11):1255. doi: 10.3390/vaccines12111255. Vaccines (Basel). 2024. PMID: 39591158 Free PMC article.
This is a single-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of Razi Cov Pars (RCP) intranasal recombinant protein subunit COVID-19 vaccine as a booster in adults. ...
This is a single-center, randomized, double-blind, placebo-controlled clinical trial to evaluate the safety and immunogenicity of Razi …
Propagation Properties of a New Human Diploid Cell Line, RAZI-HDC, and Its Suitability as a Candidate Cell Substrate for Respiratory Syncytial Virus Vaccine Production in Comparison to MRC-5.
Abbasi A, Mohammadi A, Alirezaie B, Esna-Ashari F, Sadri N, Salimi V. Abbasi A, et al. Arch Razi Inst. 2025 Feb 1;80(1):51-59. doi: 10.32592/ARI.2025.80.1.51. eCollection 2025 Feb. Arch Razi Inst. 2025. PMID: 40951571 Free PMC article.
The total cells per 25-cm(2) flask were 44.0 2.6 *105 and 41.66 2.08 *105 for MRC-5 and RAZI-HDC, respectively. The maximum cell-specific growth rate of RAZI-HDC was 316.66 20.81, while that of MRC-5 was only 340 26.45. ...The complete cytopathic effect of R …
The total cells per 25-cm(2) flask were 44.0 2.6 *105 and 41.66 2.08 *105 for MRC-5 and RAZI-HDC, respectively. The maximum cell- …
Phase II, Safety and Immunogenicity of RAZI Cov Pars (RCP) SARS Cov-2 Vaccine in Adults Aged 18-70 Years; A Randomized, Double-Blind Clinical Trial.
Mohazzab A, Fallah Mehrabadi MH, Es-Haghi A, Kalantari S, Mokhberalsafa L, Setarehdan SA, Sadeghi F, Rezaei Mokarram A, Haji Moradi M, Razaz SH, Taghdiri M, Ansarifar A, Lotfi M, Khorasani A, Nofeli M, Masoumi S, Boluki Z, Erfanpoor S, Bagheri Amiri F, Esmailzadehha N, Filsoof S, Mohseni V, Ghahremanzadeh N, Safari S, Shahsavan M, Bayazidi S, Raghami Derakhshani M, Rabiee MH, Golmoradi-Zadeh R, Khodadoost B, Solaymani-Dodaran M, Banihashemi SR. Mohazzab A, et al. J Pharm Sci. 2023 Dec;112(12):3012-3021. doi: 10.1016/j.xphs.2023.09.027. Epub 2023 Oct 11. J Pharm Sci. 2023. PMID: 37832918 Clinical Trial.
BACKGROUND: This study explores the safety and immunogenicity of the Razi-Cov-Pars (RCP) SARS Cov-2 recombinant spike protein vaccine. METHOD: In a randomized, double-blind, placebo-controlled trial, adults aged 18-70 were randomly allocated to receive selected 10 g/200 …
BACKGROUND: This study explores the safety and immunogenicity of the Razi-Cov-Pars (RCP) SARS Cov-2 recombinant spike protein vaccine …
Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models.
Banihashemi SR, Es-Haghi A, Fallah Mehrabadi MH, Nofeli M, Mokarram AR, Ranjbar A, Salman M, Hajimoradi M, Razaz SH, Taghdiri M, Bagheri M, Dadar M, Hassan ZM, Eslampanah M, Salehi Najafabadi Z, Lotfi M, Khorasani A, Rahmani F. Banihashemi SR, et al. Front Immunol. 2022 May 26;13:836745. doi: 10.3389/fimmu.2022.836745. eCollection 2022. Front Immunol. 2022. PMID: 35693788 Free PMC article.
We herein report the development of the first recombinant protein-based vaccine in Iran based on the recombinant SARS-CoV-2 spike protein in its monomeric (encompassing amino acid 1-674 for S1 and 685-1211 for S2 subunits) and trimer form (S-Trimer) formulated in the oil-in-water …
We herein report the development of the first recombinant protein-based vaccine in Iran based on the recombinant SARS-CoV-2 spike protein in …
A medieval approach to head Injuries: exploring the contributions of Ibn Zakariya al-Razi (865-925) during the golden era of Islamic medicine.
Saydo B, Khalid AW, Almealawy YF, Hulou S, Aljanabi HF, Alghamdi M, Elsousi K, Abdulrazeq HF. Saydo B, et al. J Clin Neurosci. 2025 Dec;142:111708. doi: 10.1016/j.jocn.2025.111708. Epub 2025 Oct 24. J Clin Neurosci. 2025. PMID: 41138457
Among its leading figures was Ibn Zakariya al-Razi (865-925), a Persian polymath whose work advanced medical understanding of head injuries. OBJECTIVE: This study examines al-Razi's contributions to the classification and management of cranial trauma, and their infl …
Among its leading figures was Ibn Zakariya al-Razi (865-925), a Persian polymath whose work advanced medical understanding of head in …
A Review on Rubella Vaccine: Iran (1975-2010).
Shafayi A, Mohammadi A. Shafayi A, et al. Arch Razi Inst. 2021 Jul;76(2):167-192. doi: 10.22092/ari.2021.353242.1594. Epub 2021 Jul 1. Arch Razi Inst. 2021. PMID: 34223717 Free PMC article. Review.
Ten years later in the 1975s, the rubella vaccine was developed in Razi Vaccine and serum research institute) RVSRI). In 1977, the rubella TAKAHASHI vaccine successfully passed the clinical trial and was initially used voluntarily only in the private sector. ...The current …
Ten years later in the 1975s, the rubella vaccine was developed in Razi Vaccine and serum research institute) RVSRI). In 1977, the ru …
11,546 results
You have reached the last available page of results. Please see the User Guide for more information.